Palatin Technologies (NASDAQ:PTN – Get Free Report) released its quarterly earnings results on Monday. The company reported ($1.29) EPS for the quarter, FiscalAI reports. Palatin Technologies had a negative return on equity of 115.00% and a negative net margin of 63.54%. The company had revenue of $0.36 million during the quarter.
Palatin Technologies Stock Performance
Shares of NASDAQ:PTN opened at $6.06 on Tuesday. The stock has a market cap of $10.79 million, a P/E ratio of -75.75 and a beta of 0.75. Palatin Technologies has a 12 month low of $4.51 and a 12 month high of $31.00.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on PTN shares. HC Wainwright began coverage on Palatin Technologies in a research report on Friday, November 6th. They set a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings began coverage on Palatin Technologies in a research report on Wednesday, November 4th. They set a “sell (e+)” rating on the stock. Finally, Zacks Research initiated coverage on Palatin Technologies in a report on Friday, November 6th. They set a “hold” rating on the stock. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.
Check Out Our Latest Analysis on PTN
Institutional Trading of Palatin Technologies
An institutional investor recently bought a new stake in Palatin Technologies stock. State Street Corp bought a new stake in shares of Palatin Technologies (NASDAQ:PTN – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $124,000. State Street Corp owned about 0.79% of Palatin Technologies as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 11.50% of the company’s stock.
About Palatin Technologies
Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications. The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Read More
- Five stocks we like better than Palatin Technologies
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
